NCT02050360View on ClinicalTrials.gov

"As Required Oral Sildenafil in Raynaud's Phenomenon"

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Raynaud's Phenomenon
Interventions
DRUG

Sildenafil 40 mg

DRUG

Sildenafil 80 mg

DRUG

Placebo

Trial Locations (1)

Unknown

Clinical Investigation Center - Pharmacology Unit - University Hospital of Grenoble, Grenoble

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

NCT02050360 - "As Required Oral Sildenafil in Raynaud's Phenomenon" | Biotech Hunter | Biotech Hunter